Prospectus Filed Pursuant to Rule 424(b)(2) (424b2)

The information
in this preliminary pricing supplement is not complete and may be changed. This preliminary pricing supplement is not an offer
to sell nor does it seek an offer to buy these notes in any jurisdiction where the offer or sale is not permitted.

Subject
to Completion. Dated June 19, 2017.

UBS AG

$

Capped
Leveraged MSCI EAFE
®
Index-Linked Medium-Term Notes, due

The notes will not bear interest.
The amount that you will
be paid on your notes on the stated maturity date (expected to be the third business day after the determination date) is based
on the performance of the MSCI EAFE
®
Index as measured from the trade date to and including the determination
date (expected to be between 18 and 21 months after the trade date). If the final underlier level on the determination date is
greater than the initial underlier level (set on the trade date and will be a level equal to the closing level of the underlier
on the trade date), the return on your notes will be positive, subject to the maximum settlement amount (expected to be between
$1,170.70 and $1,200.70 for each $1,000 face amount of your notes). If the final underlier level on the determination date is
equal to the initial underlier level, you will receive the face amount of your notes.
If the final underlier level
on
the determination date is less than the initial underlier level, the return on your notes will be negative.
Specifically,
you will lose 1% for every 1% negative underlier return. You could lose your entire investment in the notes.

To determine your cash settlement amount, we will calculate
the underlier return, which is the percentage increase or decrease in the final underlier level from the initial underlier level.
On the stated maturity date, for each $1,000 face amount of your notes, you will receive an amount in cash equal to:

¨

if the underlier return is
positive
(the final underlier level is
greater than
the initial underlier level), the
sum
of (i) $1,000
plus
(ii) the
product
of (a) $1,000
times
(b) the upside participation rate (expected to be 300%)
times
(c) the underlier return, subject to the maximum settlement amount;

¨

if the underlier return is
zero
(the final underlier level is
equal to
the initial underlier level), $1,000; or

¨

if the underlier return is
negative
(the final underlier level is
less
than
the initial underlier level), the
sum
of (i) $1,000
plus
(ii) the
product
of (a) the
underlier return
times
(b) $1,000.

Your investment in the notes involves certain
risks, including, among other things, our credit risk. See “Additional Risk Factors Specific To Your Notes” on
page 8 of this preliminary pricing supplement.
You should read the additional disclosure herein so that you may better
understand the terms and risks of your investment.

The estimated initial value of the notes as of the trade
date is expected to be between $950.50 and $980.50 per $1,000 face amount. The range of the estimated initial value of the notes was
determined on the date hereof by reference to UBS’ internal pricing models, inclusive of the internal funding rate. For
more information about secondary market offers and the estimated initial value of the notes, see “Additional Risk Factors
Specific To Your Notes — Fair Value Considerations” and “Additional Risk Factors Specific To Your Notes —
Limited or No Secondary Market and Secondary Market Price Considerations” beginning on page 9 of this preliminary pricing
supplement.

Original issue date:

, 2017

Original issue price*:

100.00% of the face amount

Underwriting discount*:

1.33% of the face amount

Net proceeds to the issuer:

98.67% of the face amount

* The original issue price for certain investors will be between 98.67% and 100.00% of the face amount, reflecting a foregone
underwriting discount with respect to such notes; see “Supplemental plan of distribution; secondary markets (if any)” on page 4.

Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these
notes or passed upon the accuracy or adequacy of this preliminary pricing supplement, the accompanying product supplement, the
accompanying index supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense. The notes
are not bank deposits and are not insured by the Federal Deposit Insurance Corporation or any other governmental agency.

UBS Securities LLC

Pricing Supplement dated , 2017.

The issue price, underwriting discount
and net proceeds listed above relate to the notes we sell initially. We may decide to sell additional notes after the date of the
final pricing supplement, at issue prices and with underwriting discounts and net proceeds that differ from the amounts set forth
above. The return (whether positive or negative) on your investment in the notes will depend in part on the issue price you pay
for such notes.

UBS Securities LLC, our affiliate, will purchase
the notes from UBS for distribution to one or more registered broker dealers (“dealers”). UBS Securities LLC, the dealers
or any of their respective affiliates may use this preliminary pricing supplement in market-making transactions in notes after
their initial sale.
Unless UBS, UBS Securities LLC, the dealers or any of their respective affiliates selling such notes to
you informs you otherwise in the confirmation of sale, the pricing supplement to which this preliminary pricing supplement relates
is being used in a market-making transaction
. See “Supplemental plan of distribution; secondary markets (if any)”
in this preliminary pricing supplement and “Supplemental Plan of Distribution (Conflicts of Interest)” in the accompanying
product supplement.

SUMMARY INFORMATION

UBS has filed a registration statement (including a prospectus,
as supplemented by a product supplement for the notes and an index supplement for various securities we may offer, including the
notes), with the Securities and Exchange Commission, or SEC, for the offering to which this preliminary pricing supplement relates.
Before you invest, you should read these documents and any other documents relating to this offering that UBS has filed with the
SEC for more complete information about UBS and this offering. You may obtain these documents without cost by visiting EDGAR on
the SEC website at www.sec.gov. Our Central Index Key, or CIK, on the SEC website is 0001114446. Alternatively, UBS will arrange
to send you the prospectus, the index supplement and the product supplement if you so request by calling toll-free 1-877-387-2275.

You may access these documents on the SEC website at www.sec.gov
as follows:

References to ‘‘UBS,’’
‘‘we,’’ ‘‘our’’ and ‘‘us’’ refer only to UBS AG and
not to its consolidated subsidiaries. In this preliminary pricing supplement, ‘‘notes’’ refer to the
Capped Leveraged MSCI EAFE
®
Index-Linked Medium-Term Notes, that are offered hereby,
unless the context otherwise requires. Also, references to the “accompanying product supplement’’ mean the
UBS Underlier-Linked Notes product supplement, dated May 2, 2016, references to the “accompanying index
supplement” mean the UBS index supplement dated April 29, 2016 and references to the
‘‘accompanying prospectus’’ mean the UBS prospectus titled ‘‘Debt Securities and
Warrants,’’ dated April 29, 2016.

This preliminary pricing supplement, together with the documents
listed above, contains the terms of the notes and supersedes all other prior or contemporaneous oral statements as well as any
other written materials including preliminary or indicative pricing terms, correspondence, trade ideas, structures for implementation,
sample structures, brochures or other educational materials of ours. You should carefully consider, among other things, the matters
set forth in “Additional Risk Factors Specific To Your Notes” beginning on page 8 and in “Risk Factors”
on page PS-35 in the accompanying product supplement, as the notes involve risks not associated with conventional debt securities.
We urge you to consult your investment, legal, tax and other advisors before deciding to invest in the notes.

UBS reserves the right to change the terms of, or reject any
offer to purchase, the notes prior to their issuance. In the event of any changes to the terms of the notes, UBS will notify you
and you will be asked to accept such changes in connection with your purchase. You may also choose to reject such changes in which
case UBS may reject your offer to purchase.

ii

Investor Suitability

The notes may be suitable for you if:

¨

You fully understand the risks inherent in an investment in the notes, including the risk of loss of your entire initial investment.

¨

You can tolerate a loss of all or a substantial portion
of your investment and are willing to make an investment that has the same downside market risk of an investment in the stocks
comprising the underlier (the “underlier stocks”).

¨

You believe the level of the underlier will appreciate
over the term of the notes and the final underlier level is unlikely to exceed the cap level (to be set on the trade date and expected
to be between 105.69% and 106.69% of the initial underlier level).

¨

You understand and accept that your return on the notes
is limited by the maximum settlement amount and you are willing to invest in the notes based on the maximum settlement amount (to
be set on the trade date and expected to be between $1,170.70 and $1,200.70 for each $1,000.00 face amount of your notes).

¨

You can tolerate fluctuations in the price of the notes throughout their term that may be similar to or exceed the downside fluctuations in the level of the underlier or the price
of the underlier stocks.

¨

You do not seek guaranteed current income from your
investment and are willing to forego any dividends paid on the stocks included in the underlier.

¨

You are willing to hold the notes to maturity, a
term expected to be between 18 and 21 months, and accept that there may be little or no secondary market for the
notes.

¨

You are willing to assume the credit risk of UBS for
all payments under the notes, and understand that if UBS defaults on its obligations you may not receive any amounts due to you
including any repayment of principal.

¨

You understand that the estimated initial value of
the notes determined by our internal pricing models is lower than the issue price and that should UBS Securities LLC or any affiliate
make secondary markets for the notes, the price (not including their customary bid-ask spreads) will temporarily exceed the internal
pricing model price.

The notes may not be suitable for you if:

¨

You do not fully understand the risks inherent in
an investment in the notes, including the risk of loss of your entire initial investment.

¨

You require an investment designed to guarantee a full return of principal at maturity.

¨

You cannot tolerate a loss of all or a substantial
portion of your investment and are not willing to make an investment that has the same downside market risk of an investment in
the underlier or the underlier stocks.

¨

You believe that the level of the underlier will decline
during the term of the notes or you believe the level of the underlier will appreciate over the term of the notes and that the
final underlier level is likely to exceed the cap level (to be set on the trade date and expected to be between 105.69% and 106.69%
of the initial underlier level).

¨

You seek an investment that has unlimited return potential
without a cap on appreciation and you are unwilling to invest in the notes based on the maximum settlement amount (to be set on
the trade date and expected to be between $1,170.70 and $1,200.70 for each $1,000.00 face amount of your notes).

¨

You cannot tolerate fluctuations in the price of the
notes throughout their term that may be similar to or exceed the downside fluctuations in the level of the underlier or the price
of the underlier stocks.

¨

You seek guaranteed current income from this investment
or prefer to receive the dividends paid on the underlier stocks.

¨

You are unable or unwilling to hold the notes to maturity, a term expected to be between 18 and 21 months, or you seek
an investment for which there will be an active secondary market.

¨

You are not willing to assume the credit risk of UBS for all payments under the notes.

The investor suitability considerations identified
above are not exhaustive. Whether or not the notes are a suitable investment for you will depend on your individual circumstances
and you should reach an investment decision only after you and your investment, legal, tax, accounting and other advisors have
carefully considered the suitability of an investment in the notes in light of your particular circumstances. You should also review
“Additional Risk Factors Specific To Your Notes” in this preliminary pricing supplement and the more detailed “Risk
Factors’’ in the accompanying product supplement for risks related to an investment in the notes.

Terms to be specified in accordance with the accompanying
product supplement:

¨

type of notes: notes linked to a single underlier

¨

averaging dates: not applicable

¨

cap level: yes, as described below

¨

buffer level: not applicable

¨

interest: not applicable

Face amount:
Each note will have a face amount of
$1,000; $ in the aggregate for all the offered notes; the aggregate face amount of the offered notes may be increased if the
issuer, at its sole option, decides to sell an additional aggregate face amount of the notes subsequent to the date of the final
pricing supplement. The issue price, underwriting discount, and net proceeds of the notes in the subsequent sale may differ substantially
(higher or lower) from the original issue price you paid as provided on the cover of the final pricing supplement. The return (whether
positive or negative) on your investment in the notes will depend in part on the issue price you pay for such notes.

Purchase at amount other than face amount:
The amount
we will pay you at the stated maturity date for your notes will not be adjusted based on the issue price you pay for your notes,
so if you acquire notes at a premium (or discount) to face amount and hold them to the stated maturity date, it could affect your
investment in a number of ways. The return on your investment in such notes will be lower (or higher) than it would have been had
you purchased the notes at face amount. Also, the cap level would be triggered at a lower (or
higher) percentage return than indicated below, relative to your initial investment. See “Additional Risk Factors Specific
To Your Notes — If You Purchase Your Notes at a Premium to Face Amount, the Return on Your Investment Will Be Lower Than
the Return on Notes Purchased at Face Amount and the Impact of Certain Key Terms of the Notes Will be Negatively Affected”
in this preliminary pricing supplement.

Supplemental discussion of U.S. federal income tax consequences:
You will be obligated pursuant to the terms of the notes — in the absence of a change in law, an administrative determination
or a judicial ruling to the contrary — to characterize each note for all tax purposes as a pre-paid derivative contract
in respect of the underlier, as described under “Supplemental U.S. Tax Considerations” in the accompanying product
supplement. Pursuant to this approach, it is the opinion of Cadwalader, Wickersham & Taft LLP that upon the sale, exchange
or maturity of your notes, it would be reasonable for you to recognize capital gain or loss equal to the difference, if any, between
the amount of cash you receive at such time and your tax basis in your notes. The Internal Revenue Service might not agree with
this treatment, however, in which case, the timing and character of income or loss on your note could be materially and adversely
affected.

Additionally, we will not attempt to ascertain whether any issuers
of the underlier stocks would be treated as a “passive foreign investment company” (a “PFIC”) within the
meaning of Section 1297 of the Internal Revenue Code of 1986, as amended (the “Code”). If any such entity were so treated,
certain adverse U.S. federal income tax consequences might apply to U.S. holders upon the taxable disposition (including cash settlement)
of the notes. You should refer to information filed with the Securities and Exchange Commission or an equivalent governmental authority
by such entities and consult your tax advisor regarding the possible consequences to you if any such entity is or becomes a PFIC.

Subject to the paragraph below, investors should read the discussion
under “Supplemental U.S. Tax Considerations — Non-United States Holders — Foreign Account Tax Compliance Act”
beginning on page PS-77 in the accompanying product supplement and consult their tax advisors concerning the potential application
of The Foreign Account Tax Compliance Act.

A 30% withholding tax (which may be reduced by an applicable
income tax treaty) is imposed under Section 871(m) of the Code on certain “dividend equivalents” paid or deemed paid
to a non-U.S. holder with respect to a “specified equity-linked instrument” that references one or more dividend-paying
U.S. equity securities or indices containing U.S. equity securities. The withholding tax can apply even if the instrument
does not provide for payments that reference dividends. Treasury regulations provide that the withholding tax applies to
all dividend equivalents paid or deemed paid on specified equity-linked instruments that have a delta of one (“delta one
specified equity-linked instruments”) issued after 2016 and to all dividend equivalents paid or deemed paid on all
other specified equity-linked instruments issued after 2017.

Based on our determination that the notes are not “delta-one”
with respect to the underlier or U.S. underlier stocks, our counsel is of the opinion that the notes should not be delta
one specified equity-linked instruments and thus should not be subject to withholding on dividend equivalents. Our determination
is not binding on the IRS, and the IRS may disagree with this determination. Furthermore, the application of Section 871(m) of
the Code will depend on our determinations made upon issuance of the notes. If withholding is required, we will not make payments
of any additional amounts.

2

Nevertheless, after issuance, it is
possible that your notes could be deemed to be reissued for tax purposes upon the occurrence of certain events affecting the
underlier or underlier stocks or your notes, and following such occurrence your notes could be treated as delta one
specified equity-linked instruments that are subject to withholding on dividend equivalents. It is also possible that
withholding tax or other tax under Section 871(m) of the Code could apply to the notes under these rules if a non-U.S. holder
enters, or has entered, into certain other transactions in respect of the underlier or underlier stocks or the
notes. A non-U.S. holder that enters, or has entered, into other transactions in respect of the underlier or underlier
stocks or the notes should consult its own tax advisor regarding the application of Section 871(m) of the Code to its
notes in the context of its other transactions.

Because of the uncertainty regarding the application
of the 30% withholding tax on dividend equivalents to the notes, you are urged to consult your tax advisor regarding the potential
application of Section 871(m) of the Code and the 30% withholding tax to an investment in the notes.

Pursuant to final and temporary Treasury
regulations and Notice 2015-66, the withholding and reporting requirements under FATCA generally apply to certain “withholdable
payments” and, if made after December 31, 2018, payments of certain gross proceeds on a sale or disposition and certain
foreign passthru payments made after December 31, 2018 (or, if later, the date that final regulations defining the term “foreign
pass-thru payment” are published). We will not pay additional amounts with respect to such withholding taxes discussed above.

For more information about the tax consequences of an investment
in the notes, you should review carefully the section of the accompanying product supplement entitled “Supplemental U.S.
Tax Considerations”.

Cash settlement amount (on the stated maturity date):
for each $1,000 face amount of your notes, we will pay you on the stated maturity date an amount in cash equal to:

¨

if the final underlier level is
greater than or equal to
the cap level, the maximum settlement amount;

¨

if the final underlier level is
greater than
the initial underlier level but
less than
the cap level, the
sum
of (1) $1,000
plus
(2) the
product
of (i) $1,000
times
(ii) the upside participation rate
times
(iii) the underlier return;

¨

if the final underlier level is
equal to
the initial underlier level, $1,000; or

¨

if the final underlier level is
less than
the
initial underlier level, the
sum
of (1) $1,000
plus
(2) the
product
of (i) $1,000
times
(ii) the underlier return.

Initial underlier level:
the closing level of the underlier on the trade date

Final underlier level:
the closing level of the underlier
on the determination date, except in the limited circumstances described under “General Terms of the Notes — Market
Disruption Event — Consequences of a Market Disruption Event or a Non-Trading Day” and “General Terms of the
Notes — Discontinuance of or Adjustments to the Underlier or a Basket Underlier; Alteration of Method of Calculation”
in the accompanying product supplement

Underlier return:
the
quotient
of (1) the
final underlier level
minus
the initial underlier level
divided
by (2) the initial underlier level, expressed
as a percentage

Upside participation rate (to be set on the trade date):
expected to be 300.00%

Cap level (to be set on the trade date):
a level of the
underlier expected to be between 105.69% and 106.69% of the initial underlier level

Maximum settlement amount (to be set on the trade date):
expected to be between $1,170.70 and $1,200.70

Trade date:
[ ]

Original issue date (settlement date) (to be set on the
trade date):
expected to be the fifth business day following the trade date

Determination date (to be set on the trade date):
a
specified date that is expected to be between 18 and 21 months after the trade date, subject to adjustment as described
under “General Terms of the Notes — Determination Date” in the accompanying product supplement

Stated maturity date (to be set on the trade date):
a specified date that is expected to be the third business day after the determination date, subject to adjustment as described
under “General Terms of the Notes — Stated Maturity Date” in the accompanying product supplement

Additional Market Disruption Event:
Notwithstanding any provision to the contrary in the accompanying product supplement, if the underlier is calculated and published
by the underlier sponsor, a market disruption event may occur if underlier stocks constituting 20% or more, by weight, of
the underlier or any constituent index of the underlier, or option or futures contracts, if available, relating to the underlier
or any constituent index of the underlier, or underlier stocks constituting 20% or more, by weight, of the underlier or any
constituent index of the underlier do not trade on what were the respective primary markets for those underlier stocks or
contracts, as determined by the calculation agent, including when one or more applicable markets are closed for trading under
ordinary circumstances.

3

No interest:
The offered notes will not bear interest.

No redemption:
The offered notes will not be subject
to a redemption right or price dependent redemption right.

No listing:
The offered notes will not be listed on
any securities exchange or interdealer quotation system.

Closing level:
as described under “General Terms
of the Notes — Closing Level” in the accompanying product supplement

Business day:
as described under “General Terms
of the Notes — Business Day” in the accompanying product supplement

Trading day:
When we refer to a trading day with respect
to the underlier, we mean a day on which the underlier is calculated and published by its underlier sponsor, regardless of whether
one or more of the principal securities markets for the underlier stocks are closed on that day.

Use of proceeds and hedging:
as described under “Use
of Proceeds and Hedging” in the accompanying product supplement

ERISA:
as described under “ERISA Considerations”
in the accompanying product supplement

Supplemental plan of distribution; secondary markets (if
any):
UBS will agree to sell to UBS Securities LLC, and UBS Securities LLC will agree to purchase from UBS, the aggregate
face amount of the notes specified on the front cover of this preliminary pricing supplement. UBS Securities LLC proposes initially
to offer the notes to the public at an original issue price set forth on the cover page of this pricing supplement, and to certain
unaffiliated securities dealers at such price less a concession not in excess of 1.33% of the face amount. The original issue
price for notes purchased by certain fee-based advisory accounts will be between 98.67% and 100.00% of the face amount, which
reflects a foregone underwriting discount with respect to such notes (i.e., the underwriting discount specified on the cover of
this pricing supplement with respect to such notes is 0.00%).

We expect to deliver the notes against payment therefor in
New York, New York on ,
2017, which is expected to be the fifth business day following the date of the final pricing supplement and of the pricing of the
notes. Under Rule 15c6-1 of the Securities Exchange Act of 1934, trades in the secondary market generally are required to settle
in three business days, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade
notes on any date prior to three business days before delivery will be required, by virtue of the fact that the notes are initially
expected to settle in five business days (T + 5), to specify alternative settlement arrangements to prevent a failed settlement.

Conflicts of interest
: UBS Securities
LLC is an affiliate of UBS and, as such, has a “conflict of interest” in the offering within the meaning of the Financial
Industry Regulatory Authority, Inc. (“FINRA”) Rule 5121. In addition, UBS will receive the net proceeds from the initial
public offering of the notes, thus creating an additional conflict of interest within the meaning of FINRA Rule 5121. Consequently,
the offering is being conducted in compliance with the provisions of FINRA Rule 5121.

UBS Securities LLC and its affiliates
may offer to buy or sell the notes in the secondary market (if any) at prices greater than UBS’ internal valuation
:
The value of the notes at any time will vary based on many factors that cannot be predicted. However, the price (not including
UBS Securities LLC’s or any affiliate’s customary bid-ask spreads) at which UBS Securities LLC or any affiliate would
offer to buy or sell the notes immediately after the trade date in the secondary market is expected to exceed the estimated initial
value of the notes as determined by reference to our internal pricing models. The amount of the excess will decline to zero on
a straight line basis over a period ending no later than 3 months after the trade date, provided that UBS Securities LLC may shorten
the period based on various factors, including the magnitude of purchases and other requests from and negotiated arrangements with
selling agents. Notwithstanding the foregoing, UBS Securities LLC and its affiliates are not required to make a market for the
notes and may stop making a market at any time. For more information about secondary market offers and the estimated initial value of the notes, see “Additional Risk Factors Specific To Your Notes — Fair value considerations” and “Additional Risk Factors Specific To Your Notes — Limited or No Secondary Market and Secondary Market Price Considerations” in this preliminary pricing supplement.

Calculation agent:
UBS Securities LLC

CUSIP no.:
90270KKM0

ISIN no.:
US90270KKM08

FDIC:
The notes are not bank deposits and are not
insured by the Federal Deposit Insurance Corporation or any other governmental agency.

4

HYPOTHETICAL EXAMPLES

The following table and chart are provided for purposes of
illustration only. They should not be taken as an indication or prediction of future investment results and are intended merely
to illustrate the impact that the various hypothetical final underlier levels on the determination date could have on the cash
settlement amount at maturity assuming all other variables remain constant.

The examples below are based on a range of final underlier
levels that are entirely hypothetical; no one can predict what the underlier level will be on any day throughout the life of your
notes, and no one can predict what the final underlier level will be on the determination date. The underlier has been volatile
in the past — meaning that the underlier level has changed considerably in relatively short periods — and its performance
cannot be predicted for any future period.

The information in the following examples reflects hypothetical
rates of return on the offered notes assuming that they are purchased on the original issue date at the face amount and held to
the stated maturity date. If you sell your notes in a secondary market prior to the stated maturity date, your return will depend
upon the market value of your notes at the time of sale, which may be affected by a number of factors that are not reflected in
the table below such as interest rates, the volatility of the underlier and our creditworthiness. In addition, the estimated value
of your notes at the time the terms of your notes are set on the trade date (as determined by reference to our pricing models)
will be less than the original issue price of your notes. For more information on the estimated value of your notes, see “Additional
Risk Factors Specific To Your Notes — Fair Value Considerations — The Issue Price You Pay for the Notes Will Exceed
Their Estimated Initial Value” in this preliminary pricing supplement. The information in the table also reflects the key
terms and assumptions in the box below.

Key Terms and Assumptions

Face amount

$1,000.00

Upside participation rate

300.00%

Cap level

106.19% of the initial underlier level (the midpoint of the range set forth herein)

Maximum settlement amount

$1,185.70 (the midpoint of the range set forth on the cover page of this preliminary pricing supplement)

Neither a market disruption event nor a non-trading day occurs on the originally scheduled determination date.

No change in or affecting any of the underlier stocks or the method by which the underlier sponsor calculates the underlier. Notes are purchased on original issue date at the face amount and held to the stated maturity date.

Moreover, we have not yet set the initial underlier level that
will serve as the baseline for determining the underlier return, the cap level, or the maximum settlement amount, each of which
will affect the amount that we will pay on your notes, if any, at maturity. We will not do so until the trade date. As a result,
the actual initial underlier level may differ substantially from the underlier level prior to the trade date.

For these reasons, the actual performance of the underlier
over the life of your notes, as well as the amount payable at maturity, if any, may bear little relation to the hypothetical examples
shown below or to the historical underlier levels shown elsewhere in this preliminary pricing supplement. For information about
the historical levels of the underlier during recent periods, see “The Underlier — Historical High, Low and Closing
Levels of the Underlier” in this preliminary pricing supplement. Before investing in the offered notes, you should consult
publicly available information to determine the levels of the underlier between the date of this preliminary pricing supplement
and the date of your purchase of the offered notes.

Also, the hypothetical examples shown below do not take into
account the effects of applicable taxes. Because of the U.S. tax treatment applicable to your notes, tax liabilities could affect
the after-tax rate of return on your notes to a comparatively greater extent than the after-tax return on the underlier stocks.

5

The levels in the left column of the table below represent
hypothetical final underlier levels and are expressed as percentages of the initial underlier level. The amounts in the right column
represent the hypothetical cash settlement amounts, based on the corresponding hypothetical final underlier level (expressed as
a percentage of the initial underlier level), and are expressed as percentages of the face amount of a note (rounded to the nearest
one-thousandth of a percent). Thus, a hypothetical cash settlement amount of 100.000% means that the value of the cash payment
that we would deliver for each $1,000.00 of the outstanding face amount of the offered notes on the stated maturity date would
equal 100.000% of the face amount of a note, based on the corresponding hypothetical final underlier level (expressed as a percentage
of the initial underlier level) and the assumptions noted above.

If, for example, the final underlier level were determined
to be 25.000% of the initial underlier level, the cash settlement amount that we would deliver on your notes at maturity would
be 25.000% of the face amount of your notes, as shown in the table above. As a result, if you purchased your notes on the original
issue date at the face amount and held them to the stated maturity date, you would lose 75.000% of your investment (if you purchased
your notes at a premium to face amount you would lose a correspondingly higher percentage of your investment). In addition, if
the final underlier level were determined to be 140.000% of the initial underlier level, the cash settlement amount that we would
deliver on your notes at maturity would be capped at the maximum settlement amount (expressed as a percentage of the face amount),
or 118.570% of each $1,000.00 face amount of your notes, as shown in the table above. As a result, if you held your notes to the
stated maturity date, you would not benefit from any increase in the final underlier level over 106.190% of the initial underlier
level.

The following chart also shows a graphical illustration of
the hypothetical cash settlement amounts (expressed as a percentage of the face amount of your notes) that we would pay on your
notes on the stated maturity date, if the final underlier level (expressed as a percentage of the initial underlier level) were
any of the hypothetical levels shown on the horizontal axis. The chart shows that any hypothetical final underlier level (expressed
as a percentage of the initial underlier level) of less than 100.000% (the section left of the 100.000% marker on the horizontal
axis) would result in a hypothetical cash settlement amount of less than 100.000% of the face amount of your notes (the section
below the 100.000% marker on the vertical axis) and, accordingly, in a loss of principal to the holder of the notes. The chart
also shows that any hypothetical final underlier level (expressed as a percentage of the initial underlier level) of greater than
or equal to 106.190% (the section right of the 106.190% marker on the horizontal axis) would result in a capped return on your
investment.

6

The cash settlement amounts shown above are entirely hypothetical;
they are based on market prices for the underlier stocks that may not be achieved on the determination date and on assumptions
that may prove to be erroneous. The actual market value of your notes on the stated maturity date or at any other time, including
any time you may wish to sell your notes, may bear little relation to the hypothetical cash settlement amounts shown above, and
these amounts should not be viewed as an indication of the financial return on an investment in the offered notes. The hypothetical
cash settlement amounts on notes held to the stated maturity date in the examples above assume you purchased your notes at their
face amount and have not been adjusted to reflect the actual issue price you pay for your notes. The return on your investment
(whether positive or negative) in your notes will be affected by the amount you pay for your notes. If you purchase your notes
for a price other than the face amount, the return on your investment will differ from, and may be significantly lower than, the
hypothetical returns suggested by the above examples. Please read “Additional Risk Factors Specific To Your Notes –
Market Risk” and “Additional Risk Factors Specific To Your Notes – If You Purchase Your Notes at a Premium to
Face Amount, the Return on Your Investment Will Be Lower Than the Return on Notes Purchased at Face Amount and the Impact of Certain
Key Terms of the Notes Will be Negatively Affected” in this preliminary pricing supplement.

We cannot predict the actual final underlier level or what the market value of your notes will
be on any particular trading day, nor can we predict the relationship between the underlier level and the market value of
your notes at any time prior to the stated maturity date. The actual amount that you will receive, if any, at maturity and
the rate of return on the offered notes will depend on the
actual initial underlier level, the cap level and the maximum settlement amount, which we will set on the trade date, and
the actual final underlier level determined by the calculation agent as described above. Moreover, the assumptions on which
the hypothetical returns are based may turn out to be inaccurate. Consequently, the amount of cash to be paid in respect of
your notes, if any, on the stated maturity date may be very different from the information reflected in the table and chart
above.

7

ADDITIONAL RISK FACTORS SPECIFIC
TO YOUR NOTES

An investment in your notes is subject to the
risks described below, as well as the risks described under “Considerations Relating to Indexed Securities” in the
accompanying prospectus, dated April 29, 2016, and “Risk Factors” in the accompanying product supplement, dated May
2, 2016. You should carefully review these risks as well as the terms of the notes described herein and in the accompanying prospectus,
dated April 29, 2016, as supplemented by the accompanying index supplement, dated April 29, 2016 and the accompanying product supplement,
dated May 2, 2016, of UBS. Your notes are a riskier investment than ordinary debt securities. Also, your notes are not equivalent
to investing directly in the underlier stocks, i.e., the stocks comprising the underlier to which your notes are linked. You should
carefully consider whether the offered notes are suited to your particular circumstances.

You May Lose Your Entire Investment
In The Notes

You can lose your entire investment in the notes. The cash
payment on your notes, if any, on the stated maturity date will be based on the performance of the underlier as measured from the
initial underlier level set on the trade date to the closing level on the determination date. If the final underlier level is
less
than
the initial underlier level, you will have a loss for each $1,000 of the face amount of your notes equal to the
product
of (a) the underlier return
times
(b) $1,000. Thus, you may lose your entire investment in the notes, which would include
any premium to face amount you paid when you purchased the notes.
Specifically, you will lose 1% for every 1% negative underlier
return.

Also, the market price of your notes prior to the stated
maturity date may be significantly lower than the purchase price you pay for your notes. Consequently, if you sell your notes before
the stated maturity date, you may receive far less than the amount of your investment in the notes.

The Upside Participation Rate Applies
Only At Maturity

You should be willing to hold your notes to maturity. If
you are able to sell your notes prior to maturity in the secondary market, the price you receive will likely not reflect the full
economic value of the upside participation rate of the notes and the return you realize may be less than the underlier return
multiplied by the upside participation rate, even if such return is positive. You can receive the full benefit of any positive
underlier return multiplied by the upside participation rate subject to the maximum settlement amount, only if you hold your notes
to maturity.

The Potential for the Value of Your
Notes to Increase Will Be Limited

Your ability to participate in any change in the value of
the underlier over the life of your notes and the positive effects of the upside participation rate on any positive underlier return
will be limited because of the cap level, which will be set on the trade date. The maximum settlement amount will limit the cash
settlement amount you may receive for each of your notes at maturity, no matter how much the level of the underlier may rise beyond
the cap level over the life of your notes. Accordingly, the amount payable for each of your notes may be significantly less than
it would have been had you invested directly in the underlier.

Your Notes Will Not Bear Interest

You will not receive any interest payments on your notes.
As a result, even if the cash settlement amount payable for your notes on the stated maturity date exceeds the face amount of your
notes, the overall return you earn on your notes may be less than you would have earned by investing in a conventional debt security
of comparable maturity that bears interest at a prevailing market rate.

The Notes Are Subject to the Credit
Risk of the Issuer

The notes are unsubordinated, unsecured debt obligations
of the issuer, UBS, and are not, either directly or indirectly, an obligation of any third party. Any payment to be made on the
notes, including any repayment of principal, depends on the ability of UBS to satisfy its obligations as they come due. As a result,
the actual and perceived creditworthiness of UBS may affect the market value of the notes and, in the event UBS were to default
on its obligations, you may not receive any amounts owed to you under the terms of the notes and you could lose your entire initial
investment.

Market Risk

The return on the notes is directly linked to the performance
of the underlier and indirectly linked to the value of the underlier stocks, and the extent to which the underlier return is positive
or negative. The level of the underlier can rise or fall sharply due to factors specific to the underlier stocks, as well as general
market factors, such as general market volatility and levels, interest rates and economic and political conditions. You may lose
some or all of your initial investment.

8

Fair Value Considerations

The Issue Price You Pay for the Notes
Will Exceed Their Estimated Initial Value

The issue price you pay for the notes will exceed
their estimated initial value as of the trade date due to the inclusion in the issue price of the hedging costs,
underwriting discount, issuance costs and projected profits. As of the close of the relevant markets on the trade date, we
will determine the estimated initial value of the notes by reference to our internal pricing models and it will be set forth
in the final pricing supplement. The pricing models used to determine the estimated initial value of the notes incorporate
certain variables, including the level of the underlier, the volatility of the underlier, the expected dividends on the
underlier stocks, prevailing interest rates, the term of the notes and our internal funding rate. Our internal funding rate
is typically lower than the rate we would pay to issue conventional fixed or floating rate debt securities of a similar
term. The hedging costs, issuance costs, projected profits and the difference in rates will reduce the economic value of the
notes to you. Due to these factors, the estimated initial value of the notes as of the trade date will be less than the issue
price you pay for the notes.

The Estimated Initial Value Is a Theoretical
Price; the Actual Price that You May Be Able to Sell Your Notes in Any Secondary Market (if Any) at Any Time After the Trade Date
May Differ From the Estimated Initial Value

The value of your notes at any time will vary based on many
factors, including the factors described above and in “—Market Risk” above and is impossible to predict. Furthermore,
the pricing models that we use are proprietary and rely in part on certain assumptions about future events, which may prove to
be incorrect. As a result, after the trade date, if you attempt to sell the notes in the secondary market, the actual value you
would receive may differ, perhaps materially, from the estimated initial value of the notes determined by reference to our internal
pricing models. The estimated initial value of the notes does not represent a minimum or maximum price at which we or any of our
affiliates would be willing to purchase your notes in any secondary market at any time.

Our Actual Profits May Be Greater
or Less than the Differential Between the Estimated Initial Value and the Issue Price of the Notes as of the Trade Date

We may determine the economic terms of the notes, as well
as hedge our obligations, at least in part, prior to the trade date. In addition, there may be ongoing costs to us to maintain
and/or adjust any hedges and such hedges are often imperfect. Therefore, our actual profits (or potentially, losses) in issuing
the notes cannot be determined as of the trade date and any such differential between the estimated initial value and the issue
price of the notes as of the trade date does not reflect our actual profits. Ultimately, our actual profits will be known only
at the maturity of the notes.

Limited or No Secondary Market and
Secondary Market Price Considerations

There May Be Little or No Secondary
Market for the Notes

The notes will not be listed or displayed on any securities
exchange or any electronic communications network. There can be no assurance that a secondary market for the notes will develop.
UBS Securities LLC and its affiliates may make a market in the notes, although they are not required to do so and may stop making
a market at any time. If you are able to sell your notes prior to maturity, you may have to sell them at a substantial loss. The
estimated initial value of the notes does not represent a minimum or maximum price at which we or any of our affiliates would be
willing to purchase your notes in any secondary market at any time.

The Price at which UBS Securities
LLC and Its Affiliates May Offer to Buy the Notes in the Secondary Market (if Any) May Be Greater than UBS’ Valuation of
the Notes at that Time, Greater than Any Other Secondary Market Prices Provided by Unaffiliated Dealers
(if Any) and, Depending on Your Broker, Greater than the Valuation Provided on Your Customer Account Statements

For a limited period of time following the issuance of the
notes, UBS Securities LLC or its affiliates may offer to buy or sell such notes at a price that exceeds (i) our valuation of the
notes at that time based on our internal pricing models, (ii) any secondary market prices provided by unaffiliated dealers (if
any) and (iii) depending on your broker, the valuation provided on customer account statements. The price that UBS Securities LLC
may initially offer to buy such notes following issuance will exceed the valuations indicated by our internal pricing models due
to the inclusion for a limited period of time of the aggregate value of the hedging costs, issuance costs and theoretical projected
trading profit. The portion of such amounts included in our price will decline to zero on a straight line basis over a period ending
no later than the date specified under “Summary Information – Key Terms – “Supplemental plan of distribution;
secondary markets (if any)” herein. Thereafter, if UBS Securities LLC or an affiliate makes secondary markets in the notes,
it will do so at prices that reflect our estimated value determined by reference to our internal pricing models at that time. The
temporary positive differential relative to our internal pricing models arises from requests from and arrangements made by UBS
Securities LLC with the selling agents of structured debt securities such as the notes. As described above, UBS Securities LLC
and its affiliates are not required to make a market for the notes and may stop making a market at any time. The price at which
UBS Securities LLC or an affiliate may make secondary markets at any time (if at all) will also reflect its then current bid-ask
spread for similar sized trades of structured debt securities. UBS Securities LLC reflects this temporary positive differential
on its customer statements. Investors should inquire as to the valuation provided on customer account statements provided by unaffiliated
dealers.

9

Price of Notes Prior to Maturity

The market price of the notes will be influenced by many
unpredictable and interrelated factors, including the level of the underlier; the volatility of the underlier; the dividend rate
paid on the underlier stocks; the time remaining to the maturity of the notes; interest rates in the markets; geopolitical conditions
and economic, financial, political, force majeure and regulatory or judicial events; the creditworthiness of UBS and the then current
bid-ask spread for the notes.

Impact of Fees and the Use of Internal
Funding Rates Rather than Secondary Market Credit Spreads on Secondary Market Prices

All other things being equal, the use of the internal funding
rates described above under “—Fair Value Considerations” as well as the inclusion in the original issue price
of hedging costs, underwriting discount, issuance costs and any projected profits are, subject to the temporary mitigating effect of UBS Securities LLC’s
and its affiliates’ market making premium, expected to reduce the price at which you may be able to sell the notes in any
secondary market.

The Amount Payable on Your Notes Is
Not Linked to the Level of the Underlier at Any Time Other than the Determination Date

The final underlier level will be based on the closing level
of the underlier on the determination date, except in the limited circumstances described under “General Terms of the Notes
– Consequences of a Market Disruption Event or a Non-Trading Day” and “General Terms of the Notes – Discontinuance
of or Adjustments to the Underlier or a Basket Underlier; Alteration of Method of Calculation” in the accompanying product
supplement. Therefore, if the closing level of the underlier dropped precipitously on the determination date, the cash settlement
amount for your notes may be significantly less than it would have been had the cash settlement amount been linked to the closing
level of the underlier prior to such drop in the level of the underlier. Although the actual level of the underlier on the stated
maturity date or at other times during the life of your notes may be higher than the final underlier level, you will not benefit
from the closing level of the underlier at any time other than on the determination date.

You Have No Shareholder Rights or
Rights to Receive Any Underlier Stock

Investing in your notes will not make you a holder of any
of the underlier stocks. Neither you nor any other holder or owner of your notes will have any voting rights, any right to receive
dividends or other distributions, any rights to make a claim against the underlier stocks or any other rights with respect to the
underlier stocks. Your notes will be paid in cash and you will have no right to receive delivery of any underlier stocks.

We May Sell an Additional Aggregate
Face Amount of the Notes at a Different Issue Price

At our sole option, we may decide to sell an additional aggregate
face amount of the notes subsequent to the date of the final pricing supplement. The issue price, underwriting discount, and net
proceeds of the notes in the subsequent sale may differ substantially (higher or lower) from the original issue price you paid
as provided on the cover of the final pricing supplement. The return (whether positive or negative) on your investment in the notes
will depend in part on the issue price you pay for such notes.

If You Purchase Your Notes at a Premium
to Face Amount, the Return on Your Investment Will Be Lower Than the Return on Notes Purchased at Face Amount and the Impact of
Certain Key Terms of the Notes Will be Negatively Affected

The cash settlement amount will not be adjusted based on
the original issue price you pay for the notes. If you purchase notes at a price that differs from the face amount of the notes,
then the return on your investment in such notes held to the stated maturity date will differ from, and may be substantially less
than, the return on notes purchased at face amount. If you purchase your notes at a premium to face amount and hold them to the
stated maturity date, the return on your investment in the notes will be lower than it would have been had you purchased the notes
at face amount or a discount to face amount.

In addition, the extent to which you are exposed to any negative
underlier return will depend upon the price you pay for your notes relative to face amount. For example, if you purchase your notes
at a premium to face amount, the notes may have a negative return even if the final underlier level is greater than the initial underlier level.

Lastly, the impact of the cap level on the return on
your investment, and the extent to which the cap level will diminish your exposure to any positive underlier return (as
leveraged by the upside participation rate), will also depend on the price you pay for your notes relative to face amount.
For example, if you purchase your notes at a premium to face amount, the cap level will only permit a lower percentage
increase in your investment in the notes than would have been the case for notes purchased at face amount or a discount to
face amount.

The Underlier Reflects Price Return,
Not Total Return

The return on your notes is based on the performance of the
underlier, which reflects the changes in the market prices of the underlier stocks. It is not, however, linked to a ‘‘total
return’’ index or strategy, which, in addition to reflecting those price returns, would also reflect dividends paid
on the underlier stocks. The return on your notes will not include such a total return feature or dividend component.

10

The Notes are Considered “Hold
To Maturity” Products

Generally, there is no liquid market for the notes.

Changes Affecting The Underlier Could
Have An Adverse Effect On The Value of The Notes

The policies of MSCI, the sponsor of the underlier
(the ‘‘underlier sponsor’’), concerning additions, deletions and substitutions of the underlier
stocks and the manner in which the underlier sponsor takes account of certain changes affecting those underlier stocks may
adversely affect the level of the underlier. The policies of the underlier sponsor with respect to the calculation of the
underlier could also adversely affect the level of the underlier. The underlier sponsor may discontinue or suspend
calculation or dissemination of the underlier. Any such actions could have an adverse effect on the value of the notes.

Your Notes Are Subject to Non-U.S.
Securities Market Risk

The
MSCI EAFE
®
Index is subject to risks associated with non-U.S. securities markets, specifically the regions of Europe,
Asia, Australia and the Far East. An investment in the notes linked directly or indirectly to the value of securities issued by
non-U.S. companies involves particular risks. Generally, non-U.S. securities markets may be more volatile than U.S. securities
markets, and market developments may affect non-U.S. markets differently from U.S. securities markets. Direct or indirect government
intervention to stabilize these non-U.S. markets, as well as cross shareholdings in non-U.S. companies, may affect trading prices
and volumes in those markets. There is generally less publicly available information about non-U.S. companies than about those
U.S. companies that are subject to the reporting requirements of the SEC, and non-U.S. companies are subject to accounting, auditing
and financial reporting standards and requirements that differ from those applicable to U.S. reporting companies. Securities prices
in non-U.S. countries are subject to political, economic, financial and social factors that may be unique to the particular country.
These factors, which could negatively affect the non-U.S. securities markets, include the possibility of recent or future changes
in the non-U.S. government’s economic and fiscal policies, the possible imposition of, or changes in, currency exchange laws
or other non-U.S. laws or restrictions applicable to non-U.S. companies or investments in non-U.S. equity securities and the possibility
of fluctuations in the rate of exchange between currencies. The United Kingdom has voted to leave the European Union (popularly known as “Brexit”). The effect of Brexit is uncertain,
and Brexit has and may continue to contribute to volatility in the prices of securities of companies located in Europe and currency
exchange rates, including the valuation of the euro and British pound in particular. Moreover, certain aspects of a particular
non-U.S. economy may differ favorably or unfavorably from the U.S. economy in important respects, such as growth of gross national
product, rate of inflation, capital reinvestment, resources and self-sufficiency. Finally, it will likely be more costly and difficult
to enforce the laws or regulations of a non-U.S. country or exchange.

The Notes Are Subject to Currency Exchange
Risk

Because the prices of the underlier stocks of the MSCI EAFE
®
Index are converted into U.S. dollars by the index sponsor for the purposes of calculating the level of the MSCI EAFE
®
Index, you will be exposed to currency exchange rate risk with respect to each of the currencies in which the underlier stocks
trade. Your net exposure will depend on the extent to which those currencies strengthen or weaken against the U.S. dollar and the
relative weight of the underlier stocks denominated in each of those currencies. If, taking into account the relevant weighting,
the U.S. dollar strengthens against those currencies, the level of the MSCI EAFE
®
Index will be adversely affected
and consequently the payment at maturity of the notes, if any, may be reduced.

UBS Cannot Control Actions By the Underlier Sponsor and the Underlier Sponsor Has No Obligation To
Consider Your Interests

UBS and its affiliates are not affiliated with the underlier
sponsor and have no ability to control or predict its actions, including any errors in or discontinuation of public disclosure
regarding methods or policies relating to the calculation of the underlier. The underlier sponsor is not involved in the notes
offering in any way and has no obligation to consider your interest as an owner of the notes in taking any actions that might affect
the market value of your notes.

Potential Conflict of Interest

UBS and its affiliates may engage in business related
to the underlier or underlier stocks, which may present a conflict between the obligations of UBS and you, as a holder of the
notes. There are also potential conflicts of interest between you and the calculation agent, which will be an affiliate of
UBS. The calculation agent will determine the underlier return and the cash settlement amount based on the closing level of
the underlier on the determination date. The calculation agent can postpone the determination of the final underlier level if
a market disruption event occurs and is continuing on the determination date. As UBS determines the economic terms of the
notes, including the upside participation rate and the cap level, and such terms include hedging costs,
underwriting discount, issuance costs and projected profits, the notes represent a package of economic terms. There are other potential conflicts of
interest insofar as an investor could potentially get better economic terms if that investor entered into exchange-traded
and/or OTC derivatives or other instruments with third parties, assuming that such instruments were available and the
investor had the ability to assemble and enter into such instruments.

11

Furthermore, given that UBS Securities LLC and its affiliates
temporarily maintain a market making premium, it may have the effect of discouraging UBS Securities LLC and its affiliates from
recommending the sale of your notes in the secondary market. UBS or its affiliates may earn additional profits (or potentially
incur losses) as a result of payments pursuant to such hedging activities. In performing these duties, the economic interests of
UBS, UBS Securities LLC, the dealers or their respective affiliates are potentially adverse to your interests as an investor in
the notes. Additionally, hedging activities may adversely affect the market value of your notes and the amount we will pay on your
notes.

Potentially Inconsistent Research,
Opinions or Recommendations By UBS

UBS and its affiliates publish research from time to time
on financial markets and other matters that may influence the value of the notes, or express opinions or provide recommendations
that are inconsistent with purchasing or holding the

notes. Any research, opinions or recommendations expressed
by UBS or its affiliates may not be consistent with each other and may be modified from time to time without notice. Investors
should make their own independent investigation of the merits of investing in the notes and the underlier to which the notes are
linked.

Under Certain Circumstances, the Swiss
Financial Market Supervisory Authority (“FINMA”) has the Power to Take Actions That May Adversely Affect the Notes

Pursuant to article 25 et seq. of the Swiss Banking Act,
FINMA has broad statutory powers to take measures and actions in relation to UBS if it (i) is overindebted, (ii) has serious liquidity
problems or (iii) fails to fulfill the applicable capital adequacy provisions after expiration of a deadline set by FINMA. If one
of these prerequisites is met, the Swiss Banking Act grants significant discretion to FINMA to open restructuring proceedings or
liquidation (bankruptcy) proceedings in respect of, and/or impose protective measures in relation to, UBS. In particular, a broad
variety of protective measures may be imposed by FINMA, including a bank moratorium or a maturity postponement, which measures
may be ordered by FINMA either on a stand-alone basis or in connection with restructuring or liquidation proceedings. In a restructuring
proceeding, the resolution plan may, among other things, (a) provide for the transfer of UBS’s assets or a portion thereof,
together with debts and other liabilities, and contracts of UBS, to another entity, (b) provide for the conversion of UBS’s
debt and/or other obligations, including its obligations under the notes, into equity, and/or (c) potentially provide for haircuts
on obligations of UBS, including its obligations under the notes. Although no precedent exists, if one or more measures under the
revised regime were imposed, such measures may have a material adverse effect on the terms and market value of the notes and/or
the ability of UBS to make payments thereunder.

Uncertain Tax Treatment

Significant aspects of the tax treatment of the Notes are
uncertain. There are no statutory provisions, regulations, published rulings or judicial decisions addressing the characterization
for U.S. federal income tax purposes of securities with terms that are substantially the same as the notes, and we do not plan
to request a ruling from the Internal Revenue Service (“IRS”). Consequently, significant aspects of the tax treatment
of the notes are uncertain, and the IRS or a court might not agree with the treatment of the notes as pre-paid financial contracts
that are not debt. Accordingly, it is possible that your notes could alternatively be treated for tax purposes, and that the timing
and character of the income or loss on your notes could be materially and adversely affected.

The IRS released a notice that may affect the taxation of
holders of the notes. According to Notice 2008-2, the IRS and the Treasury Department are actively considering whether the holder
of an instrument similar to the notes should be required to accrue ordinary income on a current basis, and they are seeking taxpayer
comments on the subject. It is not possible to determine what guidance they will ultimately issue, if any. It is possible, however,
that under such guidance, holders of the notes will ultimately be required to accrue income currently and this could be applied
on a retroactive basis. The IRS and the Treasury Department are also considering other relevant issues, including whether additional
gain or loss from such instruments should be treated as ordinary or capital, whether foreign holders of such instruments should
be subject to withholding tax on any deemed income accruals, and whether the special “constructive ownership rules”
of Section 1260 of the Code should be applied to such instruments. Holders are urged to consult their tax advisors concerning the
significance, and the potential impact, of the above considerations. Except to the extent otherwise required by law, UBS intends
to treat your notes for United States federal income tax purposes in accordance with the treatment described above and under “Supplemental
U.S. Tax Considerations” in the accompanying product supplement, unless and until such time as the Treasury Department and
the IRS determine that some other treatment is more appropriate.

Prospective purchasers of notes should consult their tax
advisors as to the U.S. federal, state, local, non.-U.S. and other tax consequences to them of the purchase, ownership and disposition
of the notes. For more information, see ‘‘Supplemental U.S. Tax Considerations’’ in the accompanying product
supplement.

12

THE UNDERLIER

We have derived all information contained in
this preliminary pricing supplement regarding the MSCI EAFE
®
Index (“MSCI EAFE”), including without
limitation, its make-up, method of calculation and changes in its components from publicly available information. Such information
reflects the policies of, and is subject to change by MSCI Inc. UBS has not conducted any independent review or due diligence of
any publicly available information with respect to MSCI EAFE.

MSCI EAFE is a free float-adjusted market capitalization
index that is designed to measure developed market equity performance in Europe, Asia, Australia and the Far East. MSCI EAFE includes
components from all countries in Europe, Australia and the Far East that are designated by MSCI as Developed Markets.

The five largest developed market countries
included and their relative weightings as of May 31, 2017 are: Japan (23.06%), the United Kingdom (17.90%), France (10.58%), Germany
(9.56%) and Switzerland (8.95%). Other countries account for 29.96% of MSCI EAFE and include Australia, Austria, Belgium, Denmark,
Finland, Hong Kong, Ireland, Israel, Italy, the Netherlands, New Zealand, Norway, Portugal, Singapore, Spain and Sweden. With 929
constituents, the index covers approximately 85% of the free float-adjusted market capitalization in each country.

MSCI EAFE is based on the MSCI Global Investable
Market Indexes Methodology — an approach to index construction that assesses global and cross regional comparisons across
all market capitalization size, sector and style segments and combinations. This methodology aims to provide exhaustive coverage
of the relevant investment opportunity set with a strong emphasis on index liquidity, investability and replicability. MSCI EAFE
is reviewed quarterly with the objective of reflecting change in the underlying equity markets in a timely manner, while limiting
undue index turnover. During semi-annual index reviews, MSCI EAFE is rebalanced and the large and mid-capitalization cutoff points
are recalculated.

Information from outside sources is not incorporated by reference
in, and should not be considered part of, this preliminary pricing supplement or any accompanying prospectus. Information about
the MSCI EAFE, including the methodology used to calculate the MSCI EAFE, is available at http://www.msci.com/resources/factsheets/index_fact_sheet/msci-eafe-index-usd-price.pdf.
We are not incorporating by reference the website or any material it includes in this preliminary pricing supplement.

Supplemental Information with
Respect to the MSCI EAFE Index

The following information supplements the general description
of the MSCI EAFE contained in the accompanying index supplement.

MSCI has announced that, effective with the May 2016
semi-annual index review, MSCI will add the remaining free float-adjusted market capitalization of companies that traded outside
of their country of classification (“foreign listed companies”) and were added at half their free float-adjusted market
capitalization in the MSCI Country Investable Market Indexes along with the applicable MSCI Global Investable Market Index (IMI)
at the November 2015 semi-annual index review. Such companies were added to the MSCI China IMI, MSCI Hong Kong IMI, MSCI Israel
IMI and MSCI Netherlands IMI within the MSCI ACWI IMI. Such companies met the “Foreign Listing Materiality Requirement”,
which requires the aggregate market capitalization of all securities represented by foreign listings represent at least (i) 5%
of the free float-adjusted market capitalization of the relevant MSCI Country IMI and (ii) 0.05% of the free-float adjusted market
capitalization of the MSCI ACWI IMI. MSCI expects that all changes will be implemented as of the close of May 31, 2016.

Determining the Market Investable Equity Universes

Equity Universe Minimum Size Requirement: This investability
screen is applied at the company level. In order to be included in a market investable equity universe, a company must have the
required minimum market capitalization. The equity universe minimum size requirement applies to companies in all markets and is
derived as follows:



First, the companies in the developed market equity
universe are sorted in descending order of full market capitalization and the cumulative coverage of the free float-adjusted market
capitalization of the developed market equity universe is calculated for each company. Each company’s free float-adjusted
market capitalization is represented by the aggregation of the free float-adjusted market capitalization of the securities of that
company in the equity universe.

13



Second, when the cumulative free float-adjusted market
capitalization coverage of 99% of the sorted equity universe is achieved, by adding each company’s free float-adjusted market
capitalization in descending order, full market capitalization of the company that reaches the 99% threshold defines the equity
universe minimum size requirement.



The rank of this company by descending order of full
market capitalization within the developed market equity universe is noted, and will be used in determining the equity universe
minimum size requirement at the next rebalance.

As of November 2014, the equity universe minimum size
requirement was set at US $209,000,000. Companies with a full market capitalization below this level are not included in any market
investable equity universe. The equity universe minimum size requirement is reviewed and, if necessary, revised at each semi-annual
index review.

Minimum Foreign Room Requirement: This investability
screen is applied at the individual security level. For a security that is subject to a foreign ownership limit to be eligible
for inclusion in a market investable equity universe, the proportion of shares still available to foreign investors relative to
the maximum allowed (referred to as “foreign room”) must be at least 15%.

The performance of the MSCI EAFE is a free float weighted
average of the U.S. dollar values of their component securities. Prices used to calculate the component securities are the official
exchange closing prices or prices accepted as such in the relevant market. In general, all prices are taken from the main stock
exchange or exchanges in each market. In the event of a market disruption resulting in any component security price to be unavailable,
MSCI will generally use the last reported price for such component security for the purpose of performance calculation. Closing
prices are converted into U.S. dollars, as applicable, using the closing spot exchange rates calculated by WM/Reuters at 4:00 P.M.
London Time.

Information
from outside sources is not incorporated by reference in, and should not be considered part of, this preliminary pricing supplement
or any accompanying prospectus.

Historical High, Low and Closing Levels
of the Underlier

The closing level of the underlier has fluctuated in the
past and may, in the future, experience significant fluctuations. Any historical upward or downward trend in the closing level
of the underlier during any period shown below is not an indication that the underlier is more or less likely to increase or decrease
at any time during the life of your notes.

The following table sets forth the quarterly high
and low closing levels for the underlier, based on the daily closing level as reported by Bloomberg
Professional
®
service (“Bloomberg”), without independent verification. UBS has not conducted any
independent review or due diligence of publicly available information obtained from Bloomberg. The closing level of the
underlier on June 16, 2017 was 1,892.93.
Past performance of the underlier is not indicative of the future performance of the
underlier.

As of the date of this preliminary pricing supplement, available information for the second calendar quarter of 2017
includes data for the period from April 3, 2017 through June 16, 2017. Accordingly, the ‘‘Quarterly Closing
High,’’ ‘‘Quarterly Closing Low’’ and ‘‘Quarterly Close’’ data
indicated are for this shortened period only and do not reflect complete data for the second calendar quarter of 2017.

14

The graph below illustrates the performance of the underlier
from January 3, 2007 through June 16, 2017, based on information from Bloomberg.

We have not authorized anyone to provide any information
or to make any representations other than those contained or incorporated by reference in this preliminary pricing supplement,
the accompanying product supplement, the accompanying index supplement, or the accompanying prospectus. We take no responsibility
for, and can provide no assurance as to the reliability of, any other information that others may give you. This preliminary pricing
supplement, the accompanying product supplement, the accompanying index supplement and the accompanying prospectus is an offer
to sell only the notes offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information
contained in this preliminary pricing supplement, the accompanying product supplement, the accompanying index supplement, and the
accompanying prospectus is current only as of the respective dates of such documents.

15

TABLE OF CONTENTS
Preliminary Pricing Supplement

Page

Summary Information

ii

Investor Suitability

1

Key Terms

2

Hypothetical Examples

5

Additional Risk Factors Specific to Your Notes

8

The Underlier

13

Product Supplement dated May 2, 2016

Product Supplement Summary

PS-1

Hypothetical Returns on Underlier-Linked Notes

PS-17

Hypothetical Payment Amounts on Your Notes

PS-34

Risk Factors

PS-35

General Terms of the Notes

PS-51

Use of Proceeds and Hedging

PS-70

Supplemental U.S. Tax Considerations

PS-71

ERISA Considerations

PS-79

Supplemental Plan of Distribution (Conflicts of Interest)

PS-80

Index Supplement dated April 29, 2016

Index Supplement Summary

IS-1

Underlying Indices And Underlying Index Publishers

IS-2

Dow Jones Industrial Average
TM

IS-2

NASDAQ-100 Index
®

IS-4

Russell 2000
®
Index

IS-7

S&P 500
®
Index

IS-12

Commodity Indices

IS-17

Bloomberg Commodity Index
SM

IS-17

UBS Bloomberg Constant Maturity Commodity Index Excess Return

IS-24

Non-U.S. Indices

IS-29

EURO STOXX 50
®
Index

IS-29

FTSE
TM
100 Index

IS-31

Hang Seng China Enterprises Index

IS-35

MSCI Indexes

IS-38

MSCI-EAFE
®
Index

IS-38

MSCI
®
Emerging Markets Index
SM

IS-38

MSCI
®
Europe Index

IS-38

Prospectus dated April 29, 2016

Introduction

1

Cautionary Note Regarding Forward-Looking Statements

3

Incorporation of Information About UBS AG

5

Where You Can Find More Information

6

Presentation of Financial Information

7

Limitations on Enforcement of U.S. Laws Against UBS, Its Management and Others

7

UBS

8

Swiss Regulatory Powers

11

Use of Proceeds

12

Description of Debt Securities We May Offer

13

Description of Warrants We May Offer

33

16

Legal Ownership and Book-Entry Issuance

48

Considerations Relating to Indexed Securities

53

Considerations Relating to Securities Denominated or Payable in or Linked to a Non-U.S. Dollar Currency